Table 3.
Gene | Case no. | Type of variants | Exon | mRNA accession no. | Variants | Location in protein | ExACa | Reported/Novel | Inheritance patterns | Silico prediction toolsb | Classification according to ACMG standards | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nucleotide | Amino acid | PolyPhen ‐2 | SIFT | Human Splicing Finder | Mutation Taster | ||||||||||
CDKL5 | 52 | Heterozygous frameshift deletion | 12 | NM_003159.2 | c.1849delC | p.Arg617Valfs*4 | Upstream of three putative sites at C‐terminal | Not found | Novel | De novo | NA | NA | NA | + | Pathogenic |
73 | Heterozygous frameshift deletion | 7 | c.427_430delATCA | p.Ile143Alafs*6 | Catalytic domain | Not found | Novel | DNA of parents not available | NA | NA | NA | + | Likely pathogenic | ||
KCNQ2 | 76 | Heterozygous missense | 7 | NM_172107.3 | c.944G>A | p.Gly315Glu | Calmodulin‐binding domain Helix A | Not found | Novel | De novo | +/1 | +/0 | NA | + | Likely pathogenic |
68 | Heterozygous missense | 6 | c.850T>C | p.Tyr284His | Pore‐forming P‐loop | Not found | Novel | De novo | +/0.993 | −/0.13 | NA | + | Likely pathogenic | ||
SCN8A | 16 | Heterozygous missense | 27 | NM_014101.3 | c.4850G>A | p.Arg1617Gln | S4 of transmembrane domain IV | Not found | Reported22, 31, 32 | De novo | +/1 | +/0 | NA | + | Pathogenic |
DNM1 | 72 | Heterozygous missense | 4 | NM_004408.3 | c.431C>T | p.Pro144Leu | GTPase domain | Not found | Novel | Mother is not carrier; DNA of father not available | +/1 | +/0 | NA | + | Uncertain significance |
PNPO | 55 | Compound heterozygous missense and frameshift deletion | 5 | NM_018129.3 | c. 481C>G | p.Arg161Gly | Between helix 3 and 4 | MAF= 0.0002313 for East Asian | Reported in ClinVar (Likely pathogenic) | Mother‐carrier of p.R161G; Father‐carrier of p.Pro150Argfs*27 | +/1 | +/0 | NA | + | Likely pathogenic |
c.448_451delCCTG | p.Pro150Argfs*27 | Between strand 5 and helix 3 | Not found | Reported in ClinVar (Pathogenic/Likely pathogenic) | NA | NA | NA | + | Pathogenic | ||||||
SLC9A6 | 7 | Hemizygous splice site | Intron 6 | NM_001042537.1 | c.794‐2A>G | − | Transmembrane domain 7 | Not found | Novel | Mother‐carrier | NA | NA | + | NA | Likely Pathogenic |
13 | Hemizygous frameshift deletion and insertion (indels) | 6 | c.838_839delinsG | Leu280Alafs*17 | Extracellular region between transmembrane domain 7 and 8 | Not found | Novel | De novo | NA | NA | NA | + | Pathogenic | ||
ALG13 | 75 | Heterozygous missense | 3 | NM_001099922.2 | c.320A>G | p.Asn107Ser | Conserved domain that may be important for catalytic activity | Not found | Reported15, 33, 34, 35, 36 | De novo | −/0.437 | +/0 | NA | + | Pathogenic |
TUBA8 | 1 | Compound heterozygous missense | 3 | NM_018943.2 | c.235C>T | p.Arg79Trp | No information available | MAF=0 for East Asian | Novel | Mother‐carrier of p.Arg79Trp; father‐carrier of p.Asn186Ser | +/1 | +/0 | NA | + | Uncertain significance |
4 | c.557A>G | p.Asn186Ser | Not found | +/1 | +/0 | NA | + |
Allele frequency from the ExAC database (http://exac.broadinstitute.org/).
For Polyphen‐2, “+” indicates the variant is probably damaging and “−” indicates that it is benign. For SIFT analysis, “+” indicates the variant affects protein function and “−” indicates that it is tolerated. For Human Splicing Finder, “+” indicates the variant break the acceptor site and most probably affects splicing. For Mutation Taster, “+” indicats that it is disease causing.